KardiaAI vs ClearRead CT

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

KardiaAI

by AliveCor

ClearRead CT

by RIVERAIN TECHNOLOGIES

AI Verdict

KardiaAI specializes in analyzing ambulatory ECG rhythms for cardiac conditions like AFib and tachycardia, deploying as an API library for integration. ClearRead CT, conversely, focuses on cardiothoracic health by enhancing pulmonary nodule detection and coronary artery calcification analysis in CT scans. While both tools contribute to cardiology, they address distinct diagnostic pathways and utilize different data modalities (ECG vs. CT imaging).

Choose KardiaAI if…

Choose KardiaAI if your primary need is an FDA-cleared, AI-powered library for real-time or near real-time analysis of ambulatory ECG rhythms. This tool is ideal for integrating into mobile health applications or wearable devices to provide continuous or on-demand detection of conditions like AFib, bradycardia, and tachycardia, offering medical-grade accuracy for heart rhythm data.

View KardiaAI →

Choose ClearRead CT if…

Choose ClearRead CT if your focus is on improving the accuracy and efficiency of cardiothoracic CT scan interpretations. This AI suite is best suited for radiology departments seeking advanced pulmonary nodule detection, characterization, and tracking, as well as automated coronary artery calcification scoring, to streamline workflows and enhance diagnostic confidence.

View ClearRead CT →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	KardiaAI	ClearRead CT
Pricing	Subscription-based for advanced features and services.	Contact for pricing
Deployment	Mobile app, cloud-based.	On-premise (stand-alone server, virtual machine) and Cloud
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tie

KardiaAI focuses on user-friendly mobile and web app integration, making it accessible for direct patient or clinician use. ClearRead CT prioritizes seamless integration into existing radiology PACS workflows, enhancing efficiency for radiologists by reducing reading times. Both excel in usability within their respective operational contexts.

Clinical Value

ClearRead CT

While both tools are FDA-cleared and provide significant clinical value, ClearRead CT explicitly quantifies its impact with a '29% reduction in missed actionable nodules' and '36% faster reads'. This direct, measurable improvement in diagnostic accuracy and efficiency gives it an edge in demonstrated clinical value.

Pricing & Value

KardiaAI

KardiaAI offers transparent, subscription-based pricing with clear tiers, making its cost and value proposition readily understandable. ClearRead CT, typical for enterprise solutions, requires direct vendor contact for pricing, which reduces transparency and makes it harder for potential users to assess value without engagement.

Enterprise Readiness

ClearRead CT

ClearRead CT demonstrates strong enterprise readiness through its explicit support for on-premise and cloud deployment, seamless PACS integration, and proven operation with large healthcare institutions like the VA. KardiaAI, while HIPAA compliant and offering an API, may require more custom integration for complex enterprise environments.

Innovation

ClearRead CT

ClearRead CT features patented vessel suppression technology and automated nodule tracking and comparison, which are unique and advanced technological innovations for improving CT interpretation. KardiaAI continuously expands its ECG analysis capabilities, but ClearRead CT's patented technology represents a more distinct and foundational innovation in its field.

Support & Docs

Tie

Both tools are FDA-cleared medical software, implying a standard level of documentation and support. AliveCor provides developer documentation for its API and general customer support. Riverain Technologies offers comprehensive support, manuals, and FAQs for its enterprise clients. Without specific comparative metrics on the quality or accessibility of support for the AI components themselves, it's difficult to declare a definitive winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	KardiaAI	ClearRead CT
Name	KardiaAI	ClearRead CT
Company	AliveCor	RIVERAIN TECHNOLOGIES
Primary Application Area	AI software library for analyzing ambulatory ECG rhythms, detecting various cardiac conditions like AFib, bradycardia, and tachycardia. Categories: Cardiology AI.	AI suite for cardiothoracic health, enhancing pulmonary nodule detection and coronary artery calcification analysis in CT scans. Categories: Cardiology AI, Oncology AI, Radiology & Imaging AI.
Key Detections/Analysis	AI-powered ECG analysis library; Detection of atrial fibrillation, bradycardia, tachycardia, normal sinus rhythm, Sinus Rhythm with Premature Ventricular Contractions (PVCs), Sinus Rhythm with Wide QRS, Sinus Rhythm with Supraventricular Ectopy (SVE); ECG noise filtering.	Pulmonary Nodule Detection (solid, part-solid, ground glass); Patented Vessel Suppression; Nodule Characterization and Measurement; Automated Nodule Tracking and Comparison to Prior Exams; Coronary Artery Calcification (CAC) Scoring.
Specialties Supported	Cardiology, Emergency Medicine, Internal Medicine	Cardiology, Pulmonology, Radiology

Videos

Demos, reviews, and walkthroughs featuring KardiaAI and ClearRead CT.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate with existing clinical workflows and EHR systems, and what is the typical implementation process?

KardiaAI integrates as an API library into mobile apps and web platforms, and can automatically pull ECGs into EHR systems, partnering with leading EHR software like GE Healthcare's MUSEu2122 NX and Epic. ClearRead CT offers seamless PACS integration and vendor-neutral processing, allowing radiologists to view its content as an additional series within their native workspace without requiring extra workstations or logins.

Can you provide more specific details on the accuracy and sensitivity of each tool's primary diagnostic capabilities, and how these metrics have been validated in clinical settings?

KardiaAI demonstrates high accuracy for heart rhythm data, with studies showing 96.6% sensitivity and 94% specificity for AFib detection compared to cardiology over-read of 12-lead EKGs. ClearRead CT has shown a 29% reduction in missed actionable pulmonary nodules and improved detection rates for small nodules (u22642 mm) from 13% to 24.2%, validated in studies to improve diagnostic accuracy and reduce reading times.

For a physician practicing across multiple specialties, how do the distinct clinical applications of KardiaAI and ClearRead CT align with the needs of cardiology, pulmonology, and emergency medicine departments, respectively?

KardiaAI is highly relevant for cardiology, emergency medicine, and internal medicine, focusing on AI-powered ECG analysis for detecting various cardiac conditions like AFib, bradycardia, and tachycardia. ClearRead CT is tailored for radiology, pulmonology, and cardiology, providing advanced AI for pulmonary nodule detection and coronary artery calcification scoring from CT scans.

What is the expected learning curve for physicians and staff to become proficient with each tool, and what is the typical timeframe to realize significant clinical or operational value after implementation?

KardiaAI's integration as an API library into familiar platforms suggests a potentially low learning curve, with value realized through enhanced ECG interpretation and a 30% efficiency improvement in clinic time. ClearRead CT aims to reduce reading times by up to 36% and has been noted for its ease of installation and ability to integrate into existing workflows, suggesting a rapid time-to-value by streamlining radiology tasks.

What are the key considerations for deploying each tool across multiple clinical sites, and what kind of ongoing technical and clinical support can be expected to ensure smooth operation and physician adoption?

For KardiaAI, multi-site rollout would involve consistent API management and user training across various mobile or web platforms used by different sites. ClearRead CT, with its on-premise and cloud deployment options, offers enterprise-wide capability across all CT manufacturers and acquisition protocols, with resources like case studies and clinical evidence available to support adoption.

Are customer references or case studies available for physicians to review real-world experiences and outcomes with each tool in similar clinical environments?

Yes, both companies provide customer references and case studies. AliveCor offers case studies and clinical validation studies on its resource hub, highlighting real-world impact and efficiency improvements. Riverain Technologies also features case studies and clinical evidence from medical partners, demonstrating real-world results and successful implementations in various healthcare organizations.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring KardiaAI or ClearRead CT

Backers

Who funded each tool's parent company.